Business Context and Reporting Period
This Form 8-K Current Report was filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on July 17, 2022. The registrant is a Delaware corporation and an emerging growth company. The report details the entry into a material definitive agreement for a registered direct offering of securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $6.5 million.
- Net Proceeds: Approximately $6.0 million (after deducting placement agent fees and estimated expenses).
- Securities Issued:
- 3,500,000 shares of Common Stock.
- Pre-funded warrants to purchase up to 2,632,076 shares.
- Common warrants to purchase up to 6,132,076 shares.
- Offering Prices: $1.06 per Share and associated Common Warrant; $1.0599 per Pre-Funded Warrant and associated Common Warrant.
- Placement Agent Fees: 7.0% of gross proceeds from Shares and Pre-Funded Warrants, plus expense reimbursement up to $75,000.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement with an institutional investor and a Placement Agent Agreement with A.G.P./Alliance Global Partners. Key contractual terms include:
- Lock-Up Agreements: Directors and executive officers agreed not to sell or transfer Company securities for 90 days following the closing.
- Issuance Restrictions: The Company agreed not to conduct any issuances of Common Stock for 90 days and not to enter into variable rate transactions for 12 months following the closing.
- Warrant Terms: Pre-Funded Warrants are immediately exercisable at $0.0001. Common Warrants are exercisable six months after issuance at $1.06 and expire on the fifth anniversary of the exercisability date.
Use of Proceeds and Outlook
The Company intends to use the net proceeds from the offering for research and development expenses and general corporate purposes. The filing does not provide specific financial guidance, revenue projections, or updated risk factors beyond the standard disclosures associated with the offering.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the filing states "expected" amounts.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific redemption rights or anti-dilution provisions not detailed in the summary.
- Monitor the Company's cash burn rate to assess the runway provided by the ~$6 million in net proceeds for R&D.
- Confirm the impact of the 90-day lock-up period on insider trading activity and potential future liquidity.